Mereo Biopharma Group Stock Beta
| 0A9G Stock | 3.55 0.15 4.41% |
Mereo BioPharma Group fundamentals help investors to digest information that contributes to Mereo BioPharma's financial success or failures. It also enables traders to predict the movement of Mereo Stock. The fundamental analysis module provides a way to measure Mereo BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mereo BioPharma stock.
Mereo | Beta |
Mereo BioPharma Group Company Beta Analysis
Mereo BioPharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Mereo BioPharma Beta | 0.97 |
Most of Mereo BioPharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mereo BioPharma Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Mereo BioPharma Group has a Beta of 0.97. This is 29.2% lower than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The beta for all United Kingdom stocks is notably lower than that of the firm.
Mereo Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mereo BioPharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mereo BioPharma could also be used in its relative valuation, which is a method of valuing Mereo BioPharma by comparing valuation metrics of similar companies.Mereo BioPharma is currently under evaluation in beta category among its peers.
Mereo BioPharma returns are very sensitive to returns on the market. As the market goes up or down, Mereo BioPharma is expected to follow.
Mereo Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (38.07) % | |||
| Current Valuation | 2.68 B | |||
| Shares Owned By Insiders | 1.02 % | |||
| Shares Owned By Institutions | 68.29 % | |||
| Revenue | 1000 K | |||
| Gross Profit | 936 K | |||
| EBITDA | (37.48 M) | |||
| Net Income | (34.2 M) | |||
| Book Value Per Share | 0.47 X | |||
| Cash Flow From Operations | (38.82 M) | |||
| Earnings Per Share | (0.28) X | |||
| Target Price | 4.38 | |||
| Number Of Employees | 33 | |||
| Beta | 0.97 | |||
| Retained Earnings | (331.16 M) |
About Mereo BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mereo BioPharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mereo BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mereo BioPharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.